AVEO Announces Change to Virtual Annual Meeting of Stockholders
May 27 2020 - 3:05PM
Business Wire
AVEO Oncology (NASDAQ: AVEO) today announced that due to the
public health impact of the novel coronavirus (COVID-19) outbreak
and governmental restrictions limiting the number of people who may
gather together, and to support the health and well-being of its
stockholders, employees and communities, the location of its 2020
Annual Meeting of Stockholders (the “Annual Meeting”) has been
changed to a virtual meeting. As previously announced, the Annual
Meeting will be held on June 10, 2020 at 10:00 a.m. Eastern Time,
but will be held via live audio webcast. Stockholders will be able
to attend the Annual Meeting only via the webcast.
As described in the proxy materials for the Annual Meeting
previously distributed, stockholders are entitled to attend and
vote at the Annual Meeting if they were a stockholder at the close
of business on April 15, 2020, the record date, or hold a legal
proxy for the meeting provided by the stockholder’s bank, brokerage
firm or other nominee as of such record date. To access,
participate in, and vote at the Annual Meeting at
www.proxydocs.com/AVEO, stockholders must enter the control number
found on their proxy card, voting instruction form or notice they
previously received. You will need to register to attend the Annual
Meeting at www.proxydocs.com/AVEO by no later than Monday, June 8,
2020 at 5:00 p.m. Eastern Time. A list of registered stockholders
will also be available to record holders during the Annual
Meeting.
For additional information regarding how stockholders may
attend, participate in and/or vote at the virtual Annual Meeting,
please refer to AVEO’s additional proxy material filed with the
U.S. Securities and Exchange Commission today, which can also be
accessed on AVEO’s website at www.aveooncology.com.
Please note that the proxy card included with the proxy
materials previously distributed will not be updated to reflect the
change in location and may continue to be used to vote a
stockholder’s shares in connection with the Annual Meeting.
About AVEO
AVEO is developing an oncology pipeline designed to provide a
better life for patients with cancer. AVEO’s strategy is to focus
its resources toward development and commercialization of its
product candidates in North America, while leveraging partnerships
to support development and commercialization in other geographies.
AVEO’s lead candidate, tivozanib (FOTIVDA®) is approved in the
European Union, the United Kingdom, Norway, New Zealand and Iceland
for the treatment of adult patients with advanced renal cell
carcinoma. AVEO is working to develop and commercialize tivozanib
in North America as a treatment for renal cell carcinoma,
hepatocellular carcinoma and other cancers. Ficlatuzumab (HGF MAb)
is in a Phase 2 clinical trial in head and neck cancer and has
reported early clinical data in pancreatic cancer. AVEO’s
earlier-stage pipeline includes several monoclonal antibodies in
oncology development, including AV-203 (anti-ErbB3 MAb), AV-380
(GDF15 MAb) and AV-353 (Notch 3 MAb). For more information, please
visit AVEO’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200527005735/en/
AVEO Contact: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2024 to May 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2023 to May 2024